engleski

Prognostic significance of chromosome findings in patients with de-novo acute myelogenous leukaemia

From 1987. until 1995. 110 patients with de novo acute leukaemia were included into prospective study. Median age was 34 years (15-60). The majority of patients have AML-M2 (41%) or AML-M1 subtype (23%) according to FAB. Thirteen (12%) patients have AML-M3 subtype. AML-M4 was observed in 13 patients (12%) and AML-M5 in 9 patients (8%).In five patients (4%) a diagnosis of AML-M6 was established. Cytogenetic abnormalities were found in 79 (72%) patients. Thirty (27%) patients were classified as a good prognostic group, 43 pts. (39%) as a poor prognostic group, and 37 (34%) as intermediate group. Complete remission was obtained in 81% of patients with good karyotype, in 65% patients with intermediate karyotype and in only 37% in poor prognostic group (p=0.001). Probability of relapse for patients with poor karyotype is 82%, for intermediate group 68% and for patients with good karyotype 56% (p=0.05). In multivariate analysis older patients with poor karyotype, with AML-M4 or AML-M5 subtype, low number of platelets and/or high number of WBC at diagnosis have high probability of induction treatment failure and low probability of disease free survival.

acute myelogenous leukemia; cytogenetics; prognosis

nije evidentirano